Pooled analysis of p53 mutations in hematological malignancies

Human Mutation

Volumn 12, Issue 1, 1998, Pages 4-18

  Prokocimer, Miron ^a   Unger, Ron ^b   Rennert, Hedy S ^c   Rotter, Varda ^d   Rennert, Gad ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c CARMEL MEDICAL CENTER   (Israel)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Etiological factors; Hematological malignancies; Molecular mechanisms; p53 Mutations

Indexed keywords

ACUTE LEUKEMIA; CARCINOGENESIS; CHRONIC LEUKEMIA; GENE DELETION; GENE INSERTION; HUMAN; LYMPHOMA; MISSENSE MUTATION; MYELODYSPLASTIC SYNDROME; NONSENSE MUTATION; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

AMINO ACID SUBSTITUTION; GENES, P53; HEMATOLOGIC NEOPLASMS; HUMANS; MUTATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031799459     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1004(1998)12:1<4::AID-HUMU2>3.0.CO;2-G     Document Type: Review

References (159)

1. Abo J, Inokuchi K, Dan K, Nomura T (1993) p53 and N-ras mutations in two new leukemia cell lines established from a patient with multilineage CD7-positive acute leukemia. Blood 82:2829-2836.
2. Adamson DJA, Dawson AD, Bennett B, King DJ, Haites NE (1995) p53 mutations in the myelodysplastic syndromes. Br J Haematol 89 61-66.
3. Ahuja H, Bar-Eli M, Arlin Z, Advani S, Allen SL, Goldman J, Snyder D, Foti A, Cline M (1991) The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest 87:2042-2047.
4. Arrowsmith CH, Murin P (1996) New insights into p53 function from structural studies. Oncogene 12:1379-1385.
5. Baldini L, Fracchiolla NS, Cro LM, Trecca D, Romitti L, Polli E, Maiolo AT, Neri A (1994) Frequent p53 gene involvement in splenic B-cell leukemia/lymphomas of possible marginal zone origin. Blood 84:270-278.
6. Ballerini P, Gaidano G, Gong JZ, Tassi V, Saglio G, Knowles DM, Dalla-Favera R (1993) Multiple genetics lesions in acquired immunodeficiency syndrome related non-Hodgkins lymphoma. Blood 81:166-176.
7. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1976) Proposal for the classification of the acute leukemias. Br J Haematol 33:451-458.
8. Beroud C, Verdier F, Soussi T (1996) p53 gene mutation: Software and data base. Nucleic Acids Res 24:147-150.
9. Bhatia K, Goldschmidts W, Gutierrez M, Gaidano G, Dalla-Favera R, Magrath I (1993) Hemi or homozygozity, a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenic effect. FASEB J 7:951-956.
10. Bhatia K, Guttierrez MI, Magrath IT (1992a) A novel mutation in the p53 gene in a Burkitt's lymphoma cell line. Hum Mol Genet 1:207-208.
11. Bhatia KG, Gutierrez MI, Huppi K, Siwarski D, Magrath IT (1992b) The pattern of p53 mutations in Burkitt's lymhoma differs from that of solid tumors. Cancer Res 52:4273-4276.
12. Bi S, Hughes T, Bungey J, Chase A, de Fabritiis P, Goldman JM (1992) p53 in chronic myeloid leukemia cell lines. Leukemia 6:839-842.
13. Binet JL, Auqier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boium P, Lesty C, Dualt MT, Monconduit M, Belabbes S, Gremy F (1981) A new prognostic classification of chronic lymphocytic leukemia derived from multivariete survival analysis. Cancer 48:198-206.
14. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PHM, Binchy A, Crowther D, Craft AW, Eden OB, Evans DGR, Thompson E, Mann JR, Martin J, Mitchell ELD, Santibanez-Koref MF (1994) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraument families. Cancer Res 54:1298-1304.
15. Brugieres L, Gardes M, Moutou C, Chompret A, Meresse V, Martin A, Poisson N, Flamant F, Bonaiti-Pellie C, Lemerle J, Feunteun J (1993) Screening for germ line p53 mutations in children with malignant tumors and a family history of cancer. Cancer Res 53:452-455.
16. Buhler-Leclerc M, Gratwohl A, Senn HP (1993) Occurrence of point mutations in p53 gene is not increased in patients with acute myeloid leukemia carrying an activating N-ras mutation. Br J Haematol 84:443-450.
17. Carrielo NF, Beroud C, Soussi T (1994) Database and software for the analysis of mutations at the human p53 gene. Nucleic Acids Res 22:3549-3550.
18. Cesarman E, Chadburn A, Inghirami G, Gaidano G, Knowles DM (1992) Structural and functional analysis of oncogenes and tumor suppressor genes in adult T cell leukemia/lymphoma shows frequent p53 mutations. Blood 80:3205-3216.
19. Cesarman E, Inghirami G, Chadburn A, Knowles DM (1993) High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am J Pathol 143:845-856
20. Chaney SG, Sancar A (1996) DNA repair: Enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 88:1346-1360.
21. Chang F, Syrjanen S, Syrjanen K (1995) Implication of the p53 tumor suppressor gene in clinical oncology. J Clin Oncol 13:1009-1022.
22. Chang H, Benchimol S, Minden MD, Messner HA (1994) Alterations of p53 and c-myc in the clonal evolution of malignant lymphoma. Blood 83:452-459.
23. Chang YS, Lin YZ, Tsai CN, Shu CH, Tsai MS, Choo B, Liu ST (1992) Detection of mutations in the p53 gene in human head and neck carcinomas by single strand conformation polymorphism analysis. Cancer Lett 67:167-174.
24. Cheng J, Haas M (1990) Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 10:5502-5509.
25. Cho Y, Gorina S, Jeffrey PD, Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265:346-355.
26. Chow VTK, Quek HH, Tock EPC (1993) Alternative splicing of the p53 tumor suppressor gene in the Molt-4 T-lymphoblastic leukemia cell line. Cancer Lett 73 141-148.
27. Cooper DN, Youssoufian H (1988) The CpG dinucleotide and human genetic disease. Hum Genet 78:151-155.
28. Corradini P, Inghirami G, Astolli M, Ladetto M, Voena C, Ballerini P, Gu W, Nilsson K, Knowles DM, Boccadorio M, Pileri A, Dalla-Favera R (1994) Inactivation of tumor suppressor genes, p53 and Rb. 1 in plasma cell dyscrasias. Leukemia 8:758-767.
29. De Re N, Carbone A, De Vita S, Glughini A, Maestro R, Gasparoto D, Vukosavljevic T, Boiucchi M (1994) p53 protein over-expression and p53 gene abnormalities in HIV-related non-Hodgkin's lymphomas. Int J Cancer 56:662-667.
30. Diccianni MB, Yu Z, Hsiao M, Mukhergee S, Shao LE, Yu AL (1994) Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 84:3105-3112.
31. Du M, Peng H, Singh N, Isaacson PG, Pan L (1995) The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. Blood 86:4587-4593.
32. Duthu A, Debuire B, Romano Z, Ehrhart JC, Fiscella M, May E, Apello E, May P (1992) p53 mutations in Ragi cells: Characterization and localization relative to other Burkitt's lymphomas. Oncogene 7:2161-2167.
33. Edwards RH, Traub NR (1994) Alterations of the p53 gene in Epstein-Barr virus associated immunodeficiency-related lymphoma. J Virol 68:1309-1315.
34. El Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R, Newcomb EW (1993) p53 gene mutations in β-cell chrome lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82:3452-3459.
35. Farrell PJ, Allan GJ, Shanahan F, Vousden KH, Crook T (1991) p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J 10:2879-2887.
36. Farrugia MM, Duan LZ, Reis MD, Ngan BY, Berinstein NL (1994) Alterations of the p53 tumor suppressor gene in diffuse large cell lymphomas with translocations of the c-myc and BCL-2 protooncogenes. Blood 83:191-198.
37. Feinstein E, Cimino G, Gale RP, Ahmena G, Berthier R, Kishi K, Goldman J, Zaccaria A, Berrebi A, Cannani E (1991) p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci USA 88:6293-6297.
38. Feinstein E, Cimino G, Gale RP, Canaani E (1992) Initiation and progression of chronic myelogenous leukemia. Leukemia 6:37-43.
39. Felix CA, D'Amico D, Mitsudomi T, Nau MM, Lif FP, Fraumeni JJF, Cole DE, McCalla J, Reaman GH, Whang-Peng J, Knutsen T, Minna JD, Poplack DG (1992a) Absence of hereditary p53 mutations in 10 familial leukemia pedigrees. J Clin Invest 90:653-658.
40. Felix CA, Nau MM, Takahashi T, Mitsudomi T, Chiba I, Poplack DG, Reaman GH, Cole DE, Letterio JJ, Whang-Peng J, Knutsen T, Minna JD (1992b) Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. J Clin Invest 89:640-647.
41. Fenaux P, Jonveaux P, Quiquandon I, Lai JL, Pignon JM, Loucheux-Lefebvre MH, Bauters F, Berger R, Kerckaert JP (1991) p53 gene mutations in acute myeloid leukemia with 17 p monosomy. Blood 78:1652-1657.
42. Fenaux P, Jonveaux P, Quiquandon I, Preudhomme C, Lai JL, Vanrumbeke M, Loucheux-Lefebvre M, Bauters F, Berger R, Kerckaert J (1992a) Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: A report on 60 cases. Leukemia 6:42-46.
43. Fenaux P, Preudhomme C, Quiguandon I, Jonveaux P, Lai JL, Vanrumbeke M, Loucheux-Lefebre MH, Bauters F, Berger R, Kerchaert JP (1992b) Mutations of the p53 gene in acute meyloid leukemia. Br J Haematol 80:178-183.
44. Foti A, Ahuja HG, Allen SL, Koduru P, Schuster MW, Schulman P, Bar-Eli M, Cline MJ (1991) A correlation between molecular and clinical events in the evolution of chrome myelocytic leukemia to blast crisis. Blood 77:2441-2444.
45. Foti A, Bar-Eli M, Ahuja HG, Cline MJ (1990) A splicing mutation accounts for the lack of p53 expression in a CML blast crisis cell line: A novel mechanism of p53 gene inactivation. Br J Haematol 76:143-145.
46. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R (1991) p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88:5413-5417.
47. Gaidano G, Guerrasio A, Serra A, Caruzzi F, Rege-Cambrin G, Petroni D, Saglio G (1993) Mutations in the p53 and Ras family genes are associated with tumor progression of BCR/ABL negative chrome myeloprofilerative disorders. Leukemia 7:946-953.
48. Gaidano G, Newcomb EW, Gong JZ, Tassi V, Neri A, Cortlezzi A, Calori R, Baldini L, Dalla-Favera R (1994a) Analysis of alterations of oncogenes and tumor suppressor gene in chrome lymphocytic leukemia. Am J Pathol 144:1312-1319.
49. Gaidano G, Serra A, Guerrasio A, Rege-Cambrine G, Mazza U, Saglio G (1994b) Genetic analysis of p53 and RB1 tumor suppressor genes in blast crisis of chrome myeloid leukemia. Ann Hematol 68:3-7.
50. Gandini D, Aguiari GL, Cuneo A, Piva R, Castoldi GL, Senno L (1994) Novel small deletions of the p53 gene in late stage B-cell chronic lymphocytic leukemia. Br J Haematol 88:881-885.
51. Goker E, Waltham M, Kheradpour A, Trippet T, Mazumdar M, Elisseyeff Y, Schnieders B, Steinherz P, Tan C, Berman E, Bertino JR (1995) Amplification of the dihydrofolate reductage gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood 86:677-684.
52. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878.
53. Greenblatt MS, Grollman AP, Harris CC (1996) Deletions and insertions in the p53 tumor suppressor gene in human cancers: Conformation of the DNA polymerase slippage/misalignment model. Cancer Res 56:2130-2136.
54. Guinn BA, Smith M, Padua RA, Burnett A, Mills K (1995) Changing p53 mutations with the evolution of chronic myeloid leukemia from the chronic phase to blast crisis. Leuk Res 19:519-525.
55. Gupta RK, Patel K, Bodmer WF, Bodmer JG (1993) Mutation of p53 in primary biopsy material and cell lines from Hodgkin's disease. Proc Natl Acad Sci USA 90:2817-2821.
56. Hainaut F, Soussi T, Shomer B, Hollstein M, Greenblatt M, Hovig E, Harris CC, Montesano R (1997) Database of p53 gene somatic mutations in human tumors and cell lines: Updated compilation and future prospects. Nucleic Acids Res 25:151-157.
57. Hamdy N, Bhatia K, Shaker H, Kamel A, Mawla NGE, Enein MA, Yassin D, Sharkawy NE, Magrath I (1995) Molelcular epidemiology of acute lymphoblastic leukemia in Egypt. Leukemia 9:194-202.
58. Harris CC (1996) The 1995 Walter Hubert Lecture - Molecular Epidemiology of Human Cancer: Insights from the mutational analysis of p53 Tumor Suppressor Gene. Br J Cancer 73:261-269.
59. Harris CC, Hollstein M (1993) Clinical implications of the p53 tumor suppressor gene. N Engl J Med 329:1318-1327.
60. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49-53.
61. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R, Harris CC (1994) Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22:3551-3555.
62. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC (1996) Somatic point mutations in the p53 gene of human tumors and cell lines: Updated compilation. Nucleic Acids Res 24:141-146.
63. Hsiao MH, Yu AL, Yeargin J, Ku D, Haas M (1994) Nonhereditary p53 mutations in T cell acute lymphoblastic leukemia are associated with the relapse phase. Blood 83:2922-2930.
64. Hu G, Zhang W, Deisseroth AB (1992) p53 gene mutations in acute myelogenous leukemia. Br J Haematol 81:489-494.
65. Ichikawa A, Hotta T, Takagi N, Tsushita K, Kinoshita T, Nagai H, Murakami Y, Hayashi K, Saito H (1992) Mutations of p53 gene and their relation to disease progression in B cell lymphoma. Blood 79:2701-2707.
66. Ichikawa A, Hotta T, Saito H (1993) Mutations of the p53 gene in B-cell lymphoma. Leuk Lymphoma 11:21-25.
67. Imamura J, Miyoshi I, Koeffler HP (1994) p53 in hematologic malignancies. Blood 84:2412-2421.
68. Jego N, Thomas G, Hamelin R (1993) Short direct repeats flanking deletions, duplicating insertions in p53 gene in human cancers. Oncogene 8:209-212.
69. Jones PA, Bucklev JD, Henderson BE, Ross RK, Pike MC (1991) From gene to carcinogen. A rapidly evolving field in molecular epidemiology. Cancer Res 51:3617-3620.
70. Jonveaux P, Fenaux P, Quiquandon I, Pignon JM, Lai JL, Loucheux-Lefebvre MH, Goossens M, Bauters F, Berger R (1991) Mutations in the p53 gene in myelodysplastic syndromes. Oncogene 6:2243-2247.
71. Kaneki H, Mirawa S, Horlike S, Nakai H, Kashima K (1995) Tp53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. Blood 85:2189-2193
72. Kastan MB, Radin AI, Kuerbitz SJ, Onyekwere O, Wolkow CA, Civin CI, Stone KD, Woo T, Ravindranath Y, Craig RW (1991) Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res 51:4279-4286.
73. Kawamura M, Kikuchi A, Kobayashi S, Hanada R, Yamamoto K, Horibe K, Shikano T, Ueda K, Hayashi K, Sekiya T, Hayashi Y (1995) Mutations of the p53 and ras genes in childhood t (1:19)-acute lymphoblastic leukemia. Blood 85:2546-2552.
74. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, Michler RE (1995) Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85:552-565.
75. Kocialkowski S, Pezzelia F, Morrison H, Jones M, Laha S, Harris AL, Mason DY, Gatter KC (1995) Mutations in the p53 gene are not limited to classic "hot spots" and are not predictive of p53 protein, expression in high grade non- Hodgkin's lymphoma. Br J Haematol 89:55-60.
76. Koga H, Zhang S, Ichikawa T, Washiyama K, Kuroiwa T, Tanaka R, Kumanichi T (1994) Primary malignant lymphoma of the brain: Demonstration of the p53 gene mutations by PCR-SSCP analysis and immunochemistry. Nushuyo Byori 11:151-155.
77. Krawczak M, Cooper DN (1991) Gene deletions causing human genetic disease: Mechanisms of mutagenesis and the role of the local DNA sequence environment. Hum Genet 86:425-441.
78. Kunkel TA (1990) Misalignment-mediated DNA errors. Biochemistry 29:8003-8011.
79. Kurosawa, M, Okabe M, Kunieda Y, Miyazaki T (1994) p53 gene mutation in the chronic phase was not detected in the myeloid crisis of a chronic myelocytic leukemia. Blood 83:2750-2751.
80. Lai MY, Chang HC, Li HP, Ku CK, Chen PJ, Sheu JC, Huang GT, Lee PH, Chen DS (1993) Splicing mutations of the p53 gene in human hepatocellular carcinoma. Cancer Res 53:1653-1656.
81. Lai JL, Preudhomme C, Zandrecki M, Flactip M, Vanrumbeke M, Lepelley P, Wattel E, Fenaux P (1995) Myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of p53 mutations. Leukemia 9:370-381
82. Lambert IB, Napolitano RL, Fuchs RPP (1992) Carcingogen-induced frameshift mutagenesis in repetitive sequences. Proc Natl Acad Sci USA 89:1310-1314.
83. Lanza C, Gaidano G, Cimino G, Coco FL, Basso G, Sainati L, Pastore C, Nomdedeu Z, Volpe G, Parvis G, Barigone E, Mazza U, Madon E, Saglio G (1995) p53 gene inactivation in acute lymphoblastic leukemia of B cell lineage associates with chromsomal breakpoints at 11q23 and 8q24. Leukemia 9:955-959.
84. Laumann R, Jucker M, Tesch H (1992) Point mutations in the conserved regions of the p53 tumor suppressor gene do not account for the transforming process in the Jorkat acute lymphoblastic leukemia T cells. Leukemia 6:227-228.
85. Law JC, Strong LC, Chidambaram A, Ferrell RE (1991) A germ line mutation in exon 5 of the p53 in an extended cancer family. Cancer Res 51:6385-6387.
86. Lawley PD (1994) Historical origins of current concepts of carcinogenesis. Adv Cancer Res 65:17-111.
87. Lepelley P, Preudhomme CM, Vanrmnbeke M, Quesnel B, Cosson A, Fenaux P (1994) Detection of p53 mutations in hematological malignancies: Comparison between immunocytochemistry and DNA analysis. Leukemia 8:1342-1349.
88. Lo Coco FL, Gaidano G, Louie DC, Offit K, Chaganti RSK, Dalla-Favera R (1993) p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 82:2289-2295.
89. Loeb LA, Cheng KC (1990) Errors in DNA synthesis. A source of spontaneous mutations. Mutat Res 238:297-304.
90. Loechler EL (1995) How are potent bulky carcinogens able to induce such a diverse array of mutations. Mol Carcinogen 13:213-219.
91. Loechler EL (1996) The role of adduct site-specific mutagenesis in understanding how carcinogen-DNA adducts cause mutations: perspective, prospects and problems. Carcinogenesis 17:895-902.
92. Louie DC, Offit K, Jaslow R, Parsa NZ, Murty VVVS, Shluger A, Chaganti RSK (1995) p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11:14) (q13.q32) Blood 86:2892-2899.
93. Ludwig L, Schulz AS, Janssen JWG, Grunewald K, Bartram CR (1992) p53 mutations in myelodysplastic syndromes. Leukemia 6:1302-1304.
94. Lutz WK (1990) Endogenous genotoxic agents and processes as a basis of spontaneous carcinogenesis. Mutat Res 238:287-295.
95. Matolcsy A, Inghirami G, Knowles DM (1994) Molecular genetic demonstration of the diverse evolution of Richter's syndrome (chrome lymphocytic leukemia and subsequent large cell lymphoma) Blood 83:1363-1372.
96. Matozaki S, Nakagawa T, Kawaguchi R, Aozaki R, Tsutsumi M, Murayama T, Koizumi T, Nishimura R, Isobe T, Chichara K (1995) Establishment of a myeloid leukemic cell line (SKNO-1) from a patient with t(8:21) who acquired monosomy 17 during disease progression. Br J Haematol 89:805-811.
97. Matsushima AY, Cesarman E, Chadburn A, Knowles DM (1994) Post thymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations. Am J Pathol 144:573-584.
98. Mazars GR, Portier M, Zhang XG, Jourdan M, Bataille R, Theillet C, Klein B (1992) Mutations of the p53 gene in human myeloma cell lines. Oncogene 7:1015-1018.
99. Mori N, Wada M, Yokota J, Terada MT, Okada M, Teramura M, Masuda M, Hoshino S, Motoji T, Oshimi K, Mizoguchi H (1992) Mutations of the p53 tumor suppressor gene in haematologic neoplasms. Br J Haematol 81:235-240.
100. Nagai H, Kinoshita T, Imamura J, Murakami Y, Hayashi K, Mukai K, Ikeda S, Tobinai K, Saito H, Shimoyama M, Shimotohno K (1991) Genetic alterations of p53 in some patients with adult T cell leukemia. Jpn J Cancer Res 82:1421-1427.
101. Nakagawa H, Fujii H, Nakai H, Inazawa J, Mijawa S (1994) Myelomonocytic crisis with t(15:17) and a p53 mutation in a patient with chronic myelogenous leukemia. Am J Hematol 45:335-340.
102. 1. Cancer Res 52:6588-6593.
103. 1)-positive acute leukemia. Leukemia 7:1547-1551.
104. Nakamura H, Said JW, Miller CW, Koeffler HP (1993) Mutation and protein expression of p53 in acquired immunodeficiency syndrome related lymphomas. Blood 82:920-926.
105. Napolitano RL, Lambert IB, Fuchs RPP (1994) DNA sequence determinants of carcinogen-induced frameshift mutagnesis. Biochemistry 33:1311-1315.
106. Neri A, Baldini L, Trecca D, Cro L, Poli E, Maolo AT (1993) p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 81:128-135.
107. Neubauer AL, He M, Schmidt CA, Huhn D, Liu ET (1993) Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques. Leukemia 7:593-600.
108. Nguyen T, Brunson D, Crespi CL, Penman BW, Wishnok JS, Tannebaum SR (1992) DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci USA 89:3030-3034.
109. Nigro JM, Baker JS, Preisinger AC, Jessup JM, Hostetter K, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705-708.
110. Nishimura S, Asou N, Suzuchima H, Okuba T, Fujimoto T, Osato M, Yamasaki H, Lisha L, Takatsaki K (1995) p53 gene mutation and loss of heterozygosity are associated with increased risk of disease progression in adult T cell leukemia Leukemia 9:598-604.
111. O'Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn KW (1993) Role of the p53 tumor suppressor gene in the cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 53:4776-4780.
112. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. 358:80-83.
113. Pedersen-Bjergaard J, Philip P, Larsen SO, Jensen G, Byrsting K (1990) Chromosome aberrations and prognostic factors in therapy related myelodysplasia and acute nonlymphocytic leukemia. Blood 76:1083-1091.
114. Pignon JM, Vinatier I, Fanen P, Jonveaux P, Tournilhac O, Imbert M, Ruchant H, Goosens M (1994) Exhaustive analysis of the p53 gene coding sequence by denaturing gradient gel electrophoresis: Application to the detection of point mutations in acute leukemias. Hum Mutat 3:126-132.
115. Portier M, Moles JP, Mazars GR, Jeanteur P, Bataille R, Klein B, Theillet C (1992) p53 and RAS gene mutations in multiple myeloma. Oncogene 7:2539-2543.
116. Preudhomme C, Boute O, Vachee A, Magniez C, Lai JL, Gorin NC, Kerkalst JP, Bauters F, Cosson A, Fenaux P (1992a) Correlations between p53:N-Ras and NF, gene mutations in myelodysplastic syndroras (MDS) and acute myeloid leukemia (AML) Blood 80:441a.
117. Preudhomme C, Facon T, Zandecki M, Vanrumbeke M, Lai JL, Nataf E, Loucheux-Lefebvre MH, Ketchaert JP, Fenaux P (1992b) Rare occurrence of p53 gene mutations in multiple myeloma. Br J Haematol 81:440-443.
118. Preudhomme C, Rubin R, Lepelley P, Vanrumbeke M, Fenaux P (1994) Detection of serum anti p53 antibodies and their correlation between p53 mutations in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 8:1589-1591.
119. Preudhomme C, Dervite I, Wottel E, Vanrumbeke M, Flactif M, Lai JL, Hecquet B, Cappin MC, Nelken B, Gosselin B, Fenaux P (1995) Clinical significnce of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia. J Clin Oncol 13:812-820.
120. Prokocimer M, Rotter V (1994) Structure and function of p53 in normal cells and their aberrations in cancer cells: Projection on the hematologic cell lineages. Blood 84:2391-2411.
121. Pui C-H, Behm FG, Crist WM (1993) Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 82:343-362.
122. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46:219-234.
123. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yen CJ, Kern SE (1994) p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microcirculation. Cancer Res 54:3025-3033.
124. Rege-Cambrin G, Gaidano G, Serra A, Scaravaglio P, Guglielmelli T, Guerrasio A, Giovinasso B, Saglio G (1994) Analysis of the p53 gene in myeloid malignancies associated with chromosomal abnormalities involving the short arm of chromosome 17. Leukemia S23-S26.
125. Ripley LS (1990) Frameshift mutation: Determinants of specificity. Annu Rev Genet 24:189-213
126. Rosenberg S (1982) The non-Hodgkins lymphoma pathologic classification project. Cancer 49:2112-2135.
127. Sakashita A, Hattori T, Miller CW, Suzushima H, Asou N, Takatsuki K, Koeffler HP (1992) Mutations of the p53 gene in adult T cell leukemia Blood 79:477-480.
128. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, Raffeld M (1993) p53 mutation is associated with progression in follicular lymphomas. Blood 82:1994-2004.
129. Sankaranarayanan K (1991) Ionizing radiation and genetic risks. Nature of spontaneous and radiation-induced mutations in mammalian in vitro systems and mechanisms of induction of mutations by radiation. Mutat Res 258:75-97.
130. Sankaranarayanan K (1994) Estimation of genetic risks of exposure to chemical mutagens: Relevance of data on spontaneous mutations and of experience with ionizing radiation Mutat Res 304:139-158.
131. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 Cell 63:1129-1136.
132. Sen S, Takahashi R, Rami S, Freireich EJ, Stass SA (1993) Expression of differentially phosphorylated Rb and mutant p53 proteins m myeloid leukemia cell lines. Leuk Res 17:639-647.
133. Shields PG, Harris CC (1993) Principles of carcinogenesis: Chemical. In DeVita VT, Hellman S, Rosenberg SA (eds): Cancer, Principles and Practice of Oncology. 4th Ed. J.B. Lippincott Company, Philadelphia, pp 200-212.
134. Slingerland JM, Minden MD, Benchimol S (1991) Mutation of the p53 gene in human acute myelogenous leukemia. Blood 77:1500-1507.
135. Sotomatsu N, Hayashi Y, Kawamura M, Yugami S, Shitara T (1993) Establishment of a new human pre B acute lymphobastic leukemia cell line (KMO-90) with 1:19 translocation carrying p53 gene alterations. Leukemia 7:1615-1620.
136. Soudon J, Caron de Fromentel C, Bernard O, Larsen CJ (1991) Inactivation of the p53 gene expression by a splice donor site mutation in a human T cell leukemia cell line. Leukemia 5:917-920.
137. Soussi T, May P (1996) Structural aspects of the p53 protein in relation to gene evolution: A second look. J Mol Biol 260:623-637.
138. Streisinger O, Okada Y, Emrich J, Newton J, Tsugita A, Terzaghi E, Inoye M (1966) Frameshift mutations and the genetic code. Cold Spring Harbor Symp. Quant Biol 31:77-84.
139. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Hirai H, Ishikawa F, Takaku F (1991) Mutations of the p53 gene in lymphoid leukemia. Blood 77:1153-1156.
140. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Ishawa F, Takaku F, Yazaki Y, Hirai H (1992) Frequent mutations in the p53 gene in human myeloid leukemia cell line. Blood 79:2378-2383.
141. Sugimoto K, Hirano N, Toyoshima H, Chiba S, Mano H, Takaku F, Yazaki Y, Hirai H (1993) Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood 81:3022-3026.
142. Sugito S, Yamato K, Sameshima Y, Yokata J, Yano S, Miyoshi I (1991) Adult T cell leukemia: structures and expression of the p53 gene. Int J Cancer 49:880-885.
143. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Mina JD (1989) p53: A frequent target for genetic abnormalities in lung cancer. Science 246:491-494.
144. Trecca D, Longa L, Biondi A, Cro L, Calori R, Grignani F, Maiolo A, Pelicci PG, Neri A (1994) Analysis of p53 gene mutations in acute myeloid leukemia. Am J Hematol 46:304-309.
145. Trumper LH, Brady G, Bagg A, Gray D, Loke SL, Grieser H, Wagman R, Braziel R, Gascoyne RD, Vicini S, Iscove NN, Cossman J, Mak TW (1993) Single analysis of Hodgkin's and Reed-Sternberg cells: Molecular heterogeneity of gene expression and p53 mutations. Blood 81:3097-3115.
146. Venitt S (1994) Mechanisms of carcinogenesis and individual susceptibility to cancer. Clin Chem 40:1421-1425.
147. Villuendas R, Piris MA, Algara P, Sanchez-Beato M, Sanchez-Verde L, Martinez JC, Orradre JL, Garcia P, Lopez C, Martinez P (1993) The expression of p53 protein in Non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood 82:3151-3156.
148. Vogel F, Kopun M (1977) Higher frequencies of transitions among point mutations. J Mol Evol 9:159-180.
149. Wada H, Asada M, Nakazawa S, Itoh H, Kobayashi Y, Inoue T, Fukumuro K, Chan LC, Sugita K, Hanada R, Akuta N, Kobayashi N, Mizutani S (1994) Clonal expansion of p53 mutant cells in leukemia progression in vitro. Leukemia 8 53-59.
150. Wada M, Bartram CR, Nakamura H, Hachiya M, Chen DL, Borenstein J, Miller CW, Ludwig L, Hansen-Hagge TE, Ludwig WD, Reiter A, Mizoguchi H, Koeffler HP (1993) Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 82:3163-3169.
151. Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T, Murate T Saito H (1994) MDM2 oncogene overexpression in chronic lymphocytic leukemia and low grade lymphoma of B-cell origin. Blood 84:3158-3165.
152. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Mozel P, Fenaux P (1994) p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148-3157.
153. Willems PMW, Kuypers AWHM, Meijerink JPP, Holdrinet RSG, Mensink EJBM (1993) Sporadic mutations of the p53 gene in multiple myeloma and no evidence for germline mutations in three familial myeloma pedigrees. Leukemia 7:986-991.
154. Xia F, Wang X, Wang YH, Tsang NM, Yandell DW, Kelsey KT, Liber HL (1995) Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res 55:12-15.
155. Yamato K, Oka T, Hiroi M, Iwahara Y, Sugito S, Tsuchida N, Miyoshi I (1993) Expression of the p53 tumor suppressor gene in adult T cell leukemia and HTLV-1 infected cells. Jpn J Cancer Res 84:4-8.
156. Yeargin J, Cheng J, Haas M (1992) Role of the p53 tumor suppressor gene in the pathogenesis and in the suppression of acute lymphoblastic T-cell leukemia. Leukemia 6:85s-91s.
157. Yeargin J, Cheng J, Yu AL, Gjerset R, Bogart M, Haas M (1993) p53 mutation in acute T cell lymphoblistic leukemia is of somatic origin and is stable during establishment of T cell acute lymphoblastic leukemia cell lines J Clin Invest 91:2111-2117.
158. Yu Y, Xu Z, Hsie AW (1994) Adnamycin induces large deletions as a major type of mutation in CHO cells. Mutat Res 325:91-98.
159. Zhou M, Yeager AM, Smith SD, Findley HW (1995) Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild type p53 gene. Blood 85:1608-1614.